A Adoptive Cell Therapy Market, by Type (CAR-T, TCR-T, NK, and TIL), By Application (Lymphoma, Leukemia, and Others), by End User (Hospitals and Cancer Treatment Centers), and by Region (North America, Latin America, Europe

Adoptive Cell Therapy Market, by Type (CAR-T, TCR-T, NK, and TIL), By Application (Lymphoma, Leukemia, and Others), by End User (Hospitals and Cancer Treatment Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Adoptive cell therapy (ACT) is a type of immunotherapy in which T cells (a type of immune cell) are given to a patient to help the body fight diseases, such as cancer. Types of adoptive cell therapy include chimeric antigen receptor (CAR) T cells, T cell receptor (TCR) T cells, tumor infiltrating lymphocytes (TILs), and natural killer (NK) cells. Adoptive cell therapy involve use of immune cells that are grown in the lab in large numbers followed by administering them to the body to fight cancer. Sometimes, immune cells that naturally recognize melanoma are used, while other times they are modified to make them recognize and kill the melanoma cells. Adoptive cell therapy is also called T-cell transfer therapy, and cellular immunotherapy.
Market Dynamics
Key players operating in the global adoptive cell therapy market are focusing on adoption of growth strategies such as product launch, collaboration, and fundraise which are expected to drive the market growth during the forecast period. For instance, in January 2021, Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for GC012F, Gracell's FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T cell therapy for the treatment of multiple myeloma. Moreover, in November 2019, Zelluna Immunotherapy, a biopharma company developing T-cell receptor (TCR) guided adoptive cell therapy products for the treatment of multiple solid cancers, and Glycostem Therapeutics BV, a clinical stage and leading Natural Killer (NK) cell manufacturing company announced that they have entered into a development, license and supply agreement. This collaboration between Zelluna Immunotherapy and Glycostem Therapeutics BV will focus on the development and manufacture of allogeneic TCR guided NK cell therapies (TCR-NK’s) for the treatment of patients with cancer
Key features of the study:
This report provides an in-depth analysis of the global adoptive cell therapy market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global adoptive cell therapy market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
Key companies covered as a part of this study include Novartis AG, Gilead Sciences, Inc., Castle Creek Biosciences, Inc., Lineage Cell Therapeutics, Inc., Transgene SA, Cellectis, ImmunityBio, Inc., Sorrento Therapeutics, bluebird bio, Inc., Arcellx, Sana Biotechnology, Inc., Biodesix, Inc, and Laurus Labs
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global adoptive cell therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global adoptive cell therapy market
Detailed Segmentation:
Global Adoptive Cell Therapy Market, By Type :
CAR-T
TCR-T
NK
TIL
Global Adoptive Cell Therapy Market, By Application :
Lymphoma
Leukemia
Others
Global Adoptive Cell Therapy Market, By End User :
Hospitals
Cancer Treatment Centers
Global Adoptive Cell Therapy Market, By Region:
North America
By Type
CAR-T
TCR-T
NK
TIL
By Application
Lymphoma
Leukemia
Others
By End User
Hospital
Cancer Treatment Centers
By Country
U.S.
Canada
Latin America
By Type
CAR-T
TCR-T
NK
TIL
By Application
Lymphoma
Leukemia
Others
By End User
Hospital
Cancer Treatment Centers
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Type
CAR-T
TCR-T
NK
TIL
By Application
Lymphoma
Leukemia
Others
By End User
Hospital
Cancer Treatment Centers
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Type
CAR-T
TCR-T
NK
TIL
By Application
Lymphoma
Leukemia
Others
By End User
Hospital
Cancer Treatment Centers
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Type
CAR-T
TCR-T
NK
TIL
By Application
Lymphoma
Leukemia
Others
By End User
Hospital
Cancer Treatment Centers
By Country
GCC
Israel
Rest of Middle East
Africa
By Type
CAR-T
TCR-T
NK
TIL
By Application
Lymphoma
Leukemia
Others
By End User
Hospital
Cancer Treatment Centers
By Country/Region
South Africa
Central Africa
North Africa
Company Profiles
Novartis AG.*
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Strategies
Gilead Sciences, Inc.
Castle Creek Biosciences, Inc
Lineage Cell Therapeutics, Inc.
Transgene SA
Cellectis
ImmunityBio, Inc
Sorrento Therapeutics
bluebird bio, Inc.
Arcellx
Sana Biotechnology, Inc.
Biodesix, Inc
Laurus Labs
“*” marked represents similar segmentation in other categories in the respective section.